- 現金殖利率: N/A、總殖利率: 0、5年平均現金配發率: N/A
- 要留意資產負債表的未分配盈餘和配息能力, 如果為負值, 可能會無法發放股利
- 股利有2個稅要支出, 分別是綜合所得稅和健保補充保費(單筆股利達2萬元以上, 課2.11%)
| EPS YoY | 現金股利 YoY | 股票股利 YoY | 現金配發率 YoY | 股票配發率 YoY | 全部配發率 YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 (10) | -4.03 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| 2022 (9) | -4.86 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| 2021 (8) | -0.38 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| 2020 (7) | -2.43 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| 2019 (6) | -1.84 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| 2018 (5) | -3.19 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| 2017 (4) | -3.37 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| 2016 (3) | -4.10 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| EPS QoQ YoY | 本業EPS QoQ YoY | 累計EPS QoQ YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 24Q3 (20) | -0.19 | -311.11 | 44.12 | -0.13 | 69.77 | 73.47 | -0.65 | -41.3 | 62.21 |
| 24Q2 (19) | 0.09 | 116.67 | 112.86 | -0.43 | 38.57 | 50.0 | -0.46 | 14.81 | 66.67 |
| 24Q1 (18) | -0.54 | 76.62 | 20.59 | -0.70 | 59.3 | -25.0 | -0.54 | 86.6 | 20.59 |
| 23Q4 (17) | -2.31 | -579.41 | 9.41 | -1.72 | -251.02 | -82.98 | -4.03 | -134.3 | 17.08 |
| 23Q3 (16) | -0.34 | 51.43 | 59.52 | -0.49 | 43.02 | 54.63 | -1.72 | -24.64 | 25.54 |
| 23Q2 (15) | -0.70 | -2.94 | 20.45 | -0.86 | -53.57 | -16.22 | -1.38 | -102.94 | 6.12 |
| 23Q1 (14) | -0.68 | 73.33 | -15.25 | -0.56 | 40.43 | -3.7 | -0.68 | 86.01 | -15.25 |
| 22Q4 (13) | -2.55 | -203.57 | -555.36 | -0.94 | 12.96 | -225.33 | -4.86 | -110.39 | -1178.95 |
| 22Q3 (12) | -0.84 | 4.55 | -282.61 | -1.08 | -45.95 | -400.0 | -2.31 | -57.14 | -148.39 |
| 22Q2 (11) | -0.88 | -49.15 | 5.38 | -0.74 | -37.04 | 71.76 | -1.47 | -149.15 | -5.76 |
| 22Q1 (10) | -0.59 | -205.36 | -28.26 | -0.54 | -172.0 | 58.46 | -0.59 | -55.26 | -28.26 |
| 21Q4 (9) | 0.56 | 21.74 | 216.67 | 0.75 | 108.33 | 190.36 | -0.38 | 59.14 | 84.36 |
| 21Q3 (8) | 0.46 | 149.46 | 157.5 | 0.36 | 113.74 | 146.75 | -0.93 | 33.09 | 52.31 |
| 21Q2 (7) | -0.93 | -102.17 | -43.08 | -2.62 | -101.54 | -329.51 | -1.39 | -202.17 | -19.83 |
| 21Q1 (6) | -0.46 | 4.17 | 9.8 | -1.30 | -56.63 | -225.0 | -0.46 | 81.07 | 9.8 |
| 20Q4 (5) | -0.48 | 40.0 | 52.48 | -0.83 | -7.79 | -1137.5 | -2.43 | -24.62 | -32.07 |
| 20Q3 (4) | -0.80 | -23.08 | 0.0 | -0.77 | -26.23 | 0.0 | -1.95 | -68.1 | 0.0 |
| 20Q2 (3) | -0.65 | -27.45 | 0.0 | -0.61 | -52.5 | 0.0 | -1.16 | -127.45 | 0.0 |
| 20Q1 (2) | -0.51 | 49.5 | 0.0 | -0.40 | -600.0 | 0.0 | -0.51 | 72.28 | 0.0 |
| 19Q4 (1) | -1.01 | 0.0 | 0.0 | 0.08 | 0.0 | 0.0 | -1.84 | 0.0 | 0.0 |
| 年/月 | 營收 | 月增率(%) | 去年同期年增率(%) | 累計營收 | 累計營收年增率(%) | 近三月累計營收 | 存貨銷售比 | 自結稅前EPS | 自結稅前累計EPS | 備註(年增率變動50%需說明原因) |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024/10 | 1.16 | -41.94 | -26.01 | 11.58 | 22.76 | 4.29 | N/A | . | ||
| 2024/9 | 1.99 | 74.95 | 10.77 | 10.42 | 32.46 | 4.37 | 1.42 | - | ||
| 2024/8 | 1.14 | -7.82 | -31.56 | 8.43 | 38.88 | 3.49 | 1.78 | - | ||
| 2024/7 | 1.24 | 11.06 | 74.86 | 7.29 | 65.49 | 3.77 | 1.64 | . | ||
| 2024/6 | 1.11 | -21.72 | 41.86 | 6.05 | 63.7 | 3.54 | 1.8 | . | ||
| 2024/5 | 1.42 | 41.0 | 93.24 | 4.94 | 69.58 | 3.46 | 1.85 | . | ||
| 2024/4 | 1.01 | -2.46 | 89.36 | 3.52 | 61.6 | 2.74 | 2.33 | . | ||
| 2024/3 | 1.03 | 48.32 | 92.92 | 2.51 | 52.63 | 2.51 | 2.27 | . | ||
| 2024/2 | 0.7 | -11.07 | 35.36 | 1.48 | 33.2 | 2.34 | 2.44 | . | ||
| 2024/1 | 0.78 | -9.32 | 31.34 | 0.78 | 31.34 | 2.92 | 1.95 | - | ||
| 2023/12 | 0.86 | -32.18 | 32.24 | 11.57 | 9.55 | 3.7 | 1.48 | . | ||
| 2023/11 | 1.27 | -18.5 | 76.26 | 10.7 | 8.05 | 4.64 | 1.18 | . | ||
| 2023/10 | 1.56 | -13.07 | 136.48 | 9.43 | 2.68 | 5.03 | 1.09 | . | ||
| 2023/9 | 1.8 | 8.08 | 166.77 | 7.87 | -7.69 | 4.17 | 2.4 | . | ||
| 2023/8 | 1.66 | 135.5 | 232.42 | 6.07 | -22.67 | 3.15 | 3.17 | . | ||
| 2023/7 | 0.71 | -9.89 | 30.75 | 4.4 | -40.05 | 2.23 | 4.49 | . | ||
| 2023/6 | 0.78 | 6.62 | -2.43 | 3.7 | -45.67 | 2.05 | 5.06 | . | ||
| 2023/5 | 0.74 | 38.18 | 19.39 | 2.91 | -51.46 | 1.8 | 5.76 | . | ||
| 2023/4 | 0.53 | -0.63 | -1.59 | 2.18 | -59.56 | 1.58 | 6.57 | . | ||
| 2023/3 | 0.54 | 4.06 | -66.85 | 1.65 | -66.03 | 1.65 | 4.25 | . | ||
| 2023/2 | 0.51 | -13.7 | 9.94 | 1.11 | -65.61 | 1.76 | 3.97 | . | ||
| 2023/1 | 0.6 | -8.7 | -78.41 | 0.6 | -78.41 | 1.97 | 3.55 | . | ||
| 2022/12 | 0.65 | -9.61 | -81.29 | 10.56 | -73.07 | 2.04 | 3.4 | . | ||
| 2022/11 | 0.72 | 9.33 | -93.96 | 9.91 | -72.27 | 2.06 | 3.37 | . | ||
| 2022/10 | 0.66 | -1.93 | -89.49 | 9.18 | -61.33 | 1.84 | 3.78 | . | ||
| 2022/9 | 0.67 | 34.68 | -88.47 | 8.52 | -51.19 | 1.71 | 5.26 | . | ||
| 2022/8 | 0.5 | -7.36 | -93.47 | 7.85 | -32.42 | 1.84 | 4.89 | . | ||
| 2022/7 | 0.54 | -32.76 | 61.05 | 7.35 | 86.45 | 1.96 | 4.6 | . | ||
| 2022/6 | 0.8 | 30.48 | 48.86 | 6.81 | 88.82 | 1.96 | 4.65 | . | ||
| 2022/5 | 0.62 | 13.88 | 8.59 | 6.0 | 95.85 | 2.77 | 3.29 | . | ||
| 2022/4 | 0.54 | -66.53 | -15.72 | 5.39 | 115.66 | 2.62 | 3.47 | . | ||
| 2022/3 | 1.62 | 245.24 | 119.88 | 4.85 | 161.08 | 4.85 | 1.61 | 新冠肺炎疫苗自110年8月開始銷售 | ||
| 2022/2 | 0.47 | -83.06 | -12.78 | 3.23 | 188.07 | 6.72 | 1.16 | 新冠肺炎疫苗自110年8月開始銷售 | ||
| 2022/1 | 2.76 | -20.88 | 372.35 | 2.76 | 372.35 | 18.23 | 0.43 | 新冠肺炎疫苗自110年8月開始銷售 | ||
| 2021/12 | 3.49 | -70.82 | 360.82 | 39.22 | 537.13 | 21.76 | 0.35 | 新冠肺炎疫苗自110年8月開始持續銷售 | ||
| 2021/11 | 11.97 | 90.31 | 1928.72 | 35.73 | 561.89 | 24.11 | 0.31 | 新冠肺炎疫苗自110年8月開始持續銷售 | ||
| 2021/10 | 6.29 | 7.57 | 1037.37 | 23.75 | 394.09 | 19.81 | 0.38 | 新冠肺炎疫苗自110年8月開始持續銷售 | ||
| 2021/9 | 5.85 | -23.78 | 838.72 | 17.46 | 310.45 | 13.86 | 0.73 | 新冠肺炎疫苗自110年8月開始持續銷售 | ||
| 2021/8 | 7.67 | 2187.12 | 1717.83 | 11.61 | 219.83 | 8.55 | 1.18 | 主要係因新冠肺炎疫苗開始銷售所致 | ||
| 2021/7 | 0.34 | -37.85 | -32.28 | 3.94 | 22.79 | 1.44 | 6.99 | - | ||
| 2021/6 | 0.54 | -4.81 | 6.21 | 3.61 | 32.7 | 1.75 | 5.53 | - | ||
| 2021/5 | 0.57 | -11.62 | 83.08 | 3.07 | 38.8 | 1.94 | 4.97 | 主要係藥品代工收入增加所致。 | ||
| 2021/4 | 0.64 | -12.67 | 9.1 | 2.5 | 31.57 | 1.91 | 5.05 | - | ||
| 2021/3 | 0.73 | 36.93 | 33.32 | 1.86 | 41.66 | 1.86 | 1.75 | - | ||
| 2021/2 | 0.54 | -8.25 | 24.79 | 1.12 | 47.71 | 1.88 | 1.73 | - | ||
| 2021/1 | 0.58 | -22.81 | 77.64 | 0.58 | 77.64 | 1.93 | 1.68 | 主要係因藥品代工收入增加所致。 | ||
| 2020/12 | 0.76 | 28.42 | -36.29 | 6.16 | 5.38 | 1.9 | 1.7 | - | ||
| 2020/11 | 0.59 | 6.69 | 53.72 | 5.4 | 16.04 | 1.77 | 1.83 | 主要係因藥品代工收入及檢測試劑收入增加所致。 | ||
| 2020/10 | 0.55 | -11.21 | 27.32 | 4.81 | 12.65 | 1.6 | 2.02 | - | ||
| 2020/9 | 0.62 | 47.58 | 55.18 | 4.25 | 10.99 | 1.54 | 1.88 | 主要係因藥品之代工收入及技術服務收入增加所致。 | ||
| 2020/8 | 0.42 | -14.8 | 21.01 | 3.63 | 5.82 | 1.43 | 2.03 | - | ||
| 2020/7 | 0.5 | -2.51 | 44.04 | 3.21 | 4.1 | 1.31 | 2.2 | - | ||
| 2020/6 | 0.51 | 64.07 | 30.9 | 2.72 | -0.8 | 1.41 | 1.33 | - | ||
| 2020/5 | 0.31 | -47.33 | -65.03 | 2.21 | -6.04 | 1.45 | 1.29 | 本月營收較去年同期減少,主要係因108/05有授權金收入增加所致。 | ||
| 2020/4 | 0.59 | 6.7 | 43.49 | 1.9 | 29.64 | 1.57 | 1.19 | - | ||
| 2020/3 | 0.55 | 28.16 | 66.73 | 1.31 | 24.26 | 1.31 | 1.02 | 主要係因藥品之代工收入及技術服務收入增加所致。 | ||
| 2020/2 | 0.43 | 30.6 | 71.92 | 0.76 | 4.86 | 1.95 | 0.69 | 由於新冠肺炎疫情延燒，因應防疫所需，對藥品及功能性食品需求增加，帶動營收成長。 | ||
| 2020/1 | 0.33 | -72.32 | -30.52 | 0.33 | -30.52 | 1.9 | 0.7 | - | ||
| 2019/12 | 1.19 | 209.87 | 243.78 | 5.84 | 26.94 | 0.0 | N/A | 本月營收大幅增加，主要係因授權金收入及技術服務收入增加所致 | ||
| 2019/11 | 0.38 | -11.62 | -8.96 | 4.65 | 9.3 | 0.0 | N/A | - |
